Conditions: Healthy
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 33
Healthy volunteers: yes

Brief summary:
The main purpose of this study is to investigate the safety and tolerability of the study drug known as baricitinib in healthy Chinese participants. The study will measure how the body absorbs, breaks down and gets rid of baricitinib. The study will last about 20 days, not including screening. This study is for research purposes only, and is not intended to treat any medical condition.

Detailed description:

Arms:
arm 1: 2mg Baricitinib administered orally, once on Day 1 and once a day (QD) on Days 4 through 10 (7 days). arm 2: 4mg Baricitinib administered orally, once on Day 1 and QD on Days 4 through 10 (7 days). arm 3: 10mg Baricitinib administered orally, once on Day 1 and QD on Days 4 through 10 (7 days). arm 4: Placebo matching Baricitinib administered orally, once on Day 1 and QD on Days 4 through 10 (7 days).

Interventions: intervention 1: Baricitinib intervention 2: Placebo
Intervention descriptions: intervention 1: Administered orally. intervention 2: Administered orally.

Protocol document: